Literature DB >> 22454904

Phenytoin dose adjustment in epileptic patients.

G E Mawer1, P W Mullen, M Rodgers, A J Robins, S B Lucas.   

Abstract

1 A preliminary survey showed that many outpatients with partially controlled epilepsy had serum concentrations of phenytoin below the recommended therapeutic range (10-20 μg/ml). A phenytoin tolerance test was devised with the intention of predicting a more adequate daily dose for such a patient. 2 Fifteen patients were each given an oral test dose of 600 mg phenytoin sodium and the serum concentration of phenytoin was measured at intervals over 48 h; the concentration rose during the first 4 h and decayed between 12-48 h as an almost linear function of time. 3 The serum concentration/time curves were fitted by an interative computer program based on the Michaelis-Menten equation. The mean saturated rate of elimination of phenytoin was 435 mg/day and the serum concentration (K(m)) corresponding with 50% saturation was 3.8 μg/ml. The mean calculated dose of phenytoin sodium required for a steady state serum concentration of 10-20 μg/ml was 345-400 mg/day. 4 The Michaelis-Menten principle was used to predict steady state serum phenytoin concentrations in individual patients receiving daily doses of phenytoin sodium adjusted by steps of 100 mg. The serum concentrations tended to be either too low or too high. The steep relationship between phenytoin concentration and dose indicates that when the concentration reaches 5-10 μg/ml it is then appropriate to adjust dose by small steps of about 25 mg.

Entities:  

Year:  1974        PMID: 22454904      PMCID: PMC1402441          DOI: 10.1111/j.1365-2125.1974.tb00226.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Pharmacokinetic study of a patient with diphenylhydantoin toxicity.

Authors:  A J Atkinson; J M Shaw
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

2.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.

Authors:  N Gerber; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-05

3.  Management of epilepsy with diphenylhydantoin sodium. Dosage regulation for problem patients.

Authors:  H Kutt; F McDowell
Journal:  JAMA       Date:  1968-03-11       Impact factor: 56.272

4.  Microdetermination of diphenylhydantoin in biological specimens by ultraviolet spectrophotometry.

Authors:  J E Wallace
Journal:  Anal Chem       Date:  1968-05       Impact factor: 6.986

5.  Metabolic disposition of diphenylhydantoin in normal human subjects following intravenous administration.

Authors:  A J Glazko; T Chang; J Baukema; W A Dill; J R Goulet; R A Buchanan
Journal:  Clin Pharmacol Ther       Date:  1969 Jul-Aug       Impact factor: 6.875

6.  Effect of dosage increments on blood phenytoin concentrations.

Authors:  F Bochner; W D Hooper; J H Tyrer; M J Eadie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-12       Impact factor: 10.154

  6 in total
  15 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  Nonlinear assessment of phenytoin bioavailability.

Authors:  W J Jusko; J R Koup; G Alván
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

Review 3.  Differential kinetics of phenytoin in elderly patients.

Authors:  K A Bachmann; R J Belloto
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

4.  Rate of phenytoin accumulation in man: a simulation study.

Authors:  T M Ludden; J P Allen; L W Schneider; S A Stavchansky
Journal:  J Pharmacokinet Biopharm       Date:  1978-10

Review 5.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 6.  Computer assisted prescribing of drugs.

Authors:  G E Mawer
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 7.  Plasma level monitoring of anticonvulsants.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Phenytoin dosage predictions in paediatric patients.

Authors:  G J Yuen; P T Latimer; L C Littlefield; R W Mackey
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

9.  Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations.

Authors:  J W Paxton; F Rowell; J G Ratcliffe; D G Lambie; R Nanda; I D Melville; R H Johnson
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

10.  Rapid and slow release phenytoin in epileptic patients at steady state: assessment of relative bioavailability utilizing Michaelis-Menten parameters.

Authors:  R J Sawchuk; S M Pepin; I E Leppik; R J Gumnit
Journal:  J Pharmacokinet Biopharm       Date:  1982-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.